DEPAKOTE CP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPAKOTE CP (DEPAKOTE CP).
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
| Metabolism | Extensively metabolized in the liver via glucuronidation (30-50%), mitochondrial beta-oxidation (40%), and CYP450 (including CYP2C9, CYP2A6) to various metabolites. |
| Excretion | Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile. |
| Half-life | Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates. |
| Protein binding | 86-90% bound to albumin; decreased binding in renal failure, hypoalbuminemia, and at higher concentrations. |
| Volume of Distribution | 0.12-0.17 L/kg; low Vd consistent with limited extravascular distribution and high protein binding. |
| Bioavailability | Oral (immediate-release): ~92%; oral (sustained-release): about 10-20% lower peak but similar overall absorption; IV: 100%. |
| Onset of Action | Oral: 3-4 days to reach steady state; clinical antiepileptic effect may require 1-2 weeks. IV: within minutes for seizure termination. |
| Duration of Action | Oral: dosing every 12 hours maintains therapeutic levels; sustained-release forms allow once-daily dosing. Clinical effect duration parallels drug presence in CNS. |
| Molecular Weight | 144.21 |
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No specific dose adjustments for renal impairment. Caution in significant renal disease. Avoid in severe renal failure (CrCl <10 mL/min) due to risk of valproate toxicity. |
| Liver impairment | Contraindicated in patients with significant hepatic impairment, acute liver disease, or Child-Pugh class C. For mild-moderate impairment (Child-Pugh A/B), reduce dose and monitor liver function closely; no specific dose reduction established. |
| Pediatric use | Weight-based: Initial 10-15 mg/kg/day divided twice daily, titrate by 5-10 mg/kg/day weekly up to 60 mg/kg/day; maximum 60 mg/kg/day. For children <10 kg, use syrup formulation. |
| Geriatric use | Start at lower doses (250 mg twice daily), titrate slowly. Monitor for sedation, tremor, thrombocytopenia, and drug interactions. Reduce dose if clearance decreases. |
| 1st trimester | High risk of neural tube defects and other major congenital malformations. Use only if benefits outweigh risks; folate supplementation recommended. |
| 2nd trimester | Continued risk of major malformations, including neurodevelopmental deficits. Monitor drug levels and adjust dose. |
| 3rd trimester | Risk of neonatal hemorrhage, hepatic toxicity, and withdrawal. Use lowest effective dose; monitor coagulation and liver function. |
Clinical note
Comprehensive clinical and safety monograph for DEPAKOTE CP (DEPAKOTE CP).
| Placental transfer | Extensive placental transfer; fetal serum levels can reach 50-100% of maternal levels. Crosses readily throughout gestation. |
| Breastfeeding | Valproate is excreted into breast milk in low concentrations (1-10% of maternal serum levels). Although generally considered compatible, monitor infant for sedation, poor feeding, and hepatotoxicity. Alternative agents preferred if possible. |
■ FDA Black Box Warning
Hepatotoxicity: Fatal hepatic failure has occurred, especially in children under 2 years and patients with mitochondrial disorders. Pancreatitis: Fatal hemorrhagic pancreatitis has been reported.
| Common Effects | Decreased body temperature Dizziness Sleepiness Tremors Paresthesia tingling or pricking sensation Anemia low number of red blood cells Decreased sodium level in blood Liver injury Gastrointestinal disturbance Hypersensitivity Deafness Urinary incontinence Increase in body weight Pain during periods |
| Serious Effects |
Hepatic disease or significant hepatic dysfunctionUrea cycle disordersKnown hypersensitivity to valproateMitochondrial disorders caused by POLG mutations
| Precautions | Hepatotoxicity (risk factors: young age, polytherapy, metabolic disorders), pancreatitis, teratogenicity (neural tube defects), thrombocytopenia, hyperammonemia, hypothermia, multi-organ hypersensitivity reaction. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Highest risk in first trimester: neural tube defects (spina bifida, anencephaly) with 3-5% absolute risk, cardiac defects, hypospadias, cleft palate, craniofacial anomalies. Second/third trimester: fetal growth restriction, neonatal hyperglycemia, hypoglycemia, withdrawal syndrome, coagulopathy, hyperbilirubinemia, hepatotoxicity. Long-term neurodevelopmental delays (IQ reduction) irrespective of trimester. |
| Fetal Monitoring | Pre-conception: high-dose folic acid (4-5 mg/day), baseline LFTs, CBC, valproate level. During pregnancy: serial maternal valproate levels (goal 50-100 mcg/mL), LFTs, CBC every trimester. Fetal: high-resolution ultrasound with fetal echocardiography at 18-20 weeks; AFP screening for NTDs. Neonatal: monitor for bleeding, glucose, bilirubin, liver function. |
| Fertility Effects | Women: menstrual irregularities, ovulatory dysfunction, polycystic ovary-like syndrome (PCOS-like) with hyperandrogenism, elevated LH/FSH ratio, impaired fertility. Men: reduced sperm count, motility, abnormal morphology; reversible upon discontinuation. |
| Food/Dietary |
| Take with food or after meals to minimize gastrointestinal upset. Avoid alcoholic beverages due to increased sedation and hepatotoxicity risk. No specific food restrictions, but high-fat meals may alter absorption; consistent intake with meals is recommended. Grapefruit juice has not been reported to interact significantly. |
| Clinical Pearls | Depakote CP (divalproex sodium) is an extended-release formulation designed for once-daily dosing. Therapeutic drug monitoring of valproic acid trough levels is essential; target range is 50-125 mcg/mL. Liver function tests and complete blood counts should be monitored at baseline and periodically. Caution in patients with known hepatic disease, urea cycle disorders, or mitochondrial diseases. Concomitant use with carbapenem antibiotics decreases valproic acid levels significantly. Discontinuation should be gradual to avoid seizure rebound. Depakote CP is not interchangeable with other valproate products on a mg-for-mg basis due to different pharmacokinetics. |
| Patient Advice | Swallow tablets whole; do not crush, chew, or break due to extended-release properties. · Take with food to reduce gastrointestinal irritation. · Avoid alcohol while taking this medication. · Do not stop taking suddenly without consulting your doctor as seizures may worsen. · Monitor for signs of liver damage: yellowing of skin or eyes, dark urine, severe fatigue, abdominal pain. · Inform your doctor if you experience unexplained bruising, bleeding, or symptoms of pancreatitis (severe abdominal pain, nausea, vomiting). · Females of childbearing potential should use effective contraception; valproate increases risk of neural tube defects. · If taking for bipolar disorder, report any unusual mood changes or suicidal thoughts immediately. · Regular blood tests are required to check liver function, platelet count, and medication levels. · Store at room temperature away from moisture and heat. |